Online inquiry

IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11542MR)

This product GTTS-WQ11542MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11542MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8799MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ12483MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ9590MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ3955MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ7973MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ2304MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ12064MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ5487MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP 6038
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW